Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant.

Starting from our in-house library of pyrazolo[3,4-d]pyrimidines, a cross-docking simulation was conducted on Bcr-Abl T315I mutant. Among the selected compounds (2a-e), the 4-bromo derivative 2b showed the best activity against the Bcr-Abl T315I mutant. Deeper computational studies highlighted the importance of the bromine atom in the para position of the N1 side chain phenyl ring for the interaction with the T315I mutant. A series of 4-bromo derivatives was thus synthesized and biologically evaluated. Compound 2j showed a good balance of different ADME properties, high activity in cell-free assays, and a submicromolar potency against T315I Bcr-Abl expressing cells. In addition, it was converted into a water-soluble formulation by liposome encapsulation, preserving a good activity on leukemic T315I cells and avoiding the use of DMSO as solubilizing agent. In vivo studies on mice inoculated with 32D-T315I cells and treated with 2j showed a more than 50% reduction in tumor volumes.

[1]  B. Faller,et al.  High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. , 2001, Journal of medicinal chemistry.

[2]  D. Boschelli,et al.  SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. , 2003, Cancer research.

[3]  N. Rosen,et al.  A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  G. Daley,et al.  Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.

[5]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[6]  T. Clackson,et al.  Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. , 2004, Blood.

[7]  Oliver Hantschel,et al.  Regulation of the c-Abl and Bcr–Abl tyrosine kinases , 2004, Nature Reviews Molecular Cell Biology.

[8]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[9]  M. Baccarani,et al.  Dual tyrosine kinase inhibitors in chronic myeloid leukemia , 2005, Leukemia.

[10]  B. Druker,et al.  Oncogenes and Tumor Suppressors (795 articles) , 2004 .

[11]  Julian Tirado-Rives,et al.  Potential energy functions for atomic-level simulations of water and organic and biomolecular systems. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Chi‐Huey Wong,et al.  Tetrabutylammonium fluoride-assisted rapid N9-alkylation on purine ring: Application to combinatorial reactions in microtiter plates for the discovery of potent sulfotransferase inhibitors in situ , 2005, Bioorganic & Medicinal Chemistry.

[13]  Tomoko Niwa,et al.  NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. , 2005, Blood.

[14]  Julian Tirado-Rives,et al.  Molecular modeling of organic and biomolecular systems using BOSS and MCPRO , 2005, J. Comput. Chem..

[15]  M. Modugno,et al.  Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. , 2006, Journal of medicinal chemistry.

[16]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[17]  C. Brullo,et al.  Inhibition of Bcr‐Abl Phosphorylation and Induction of Apoptosis by Pyrazolo[3,4‐d]pyrimidines in Human Leukemia Cells , 2007, ChemMedChem.

[18]  T. Zhou,et al.  Crystal Structure of the T315I Mutant of Abl Kinase , 2007, Chemical biology & drug design.

[19]  Antonella Isacchi,et al.  Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. , 2007, Cancer research.

[20]  William L. Jorgensen,et al.  Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations. , 2008, Journal of the American Chemical Society.

[21]  M. Trincavelli,et al.  Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. , 2008, Journal of medicinal chemistry.

[22]  K. Shokat,et al.  Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.

[23]  P. Carrupt,et al.  High throughput UV method for the estimation of thermodynamic solubility and the determination of the solubility in biorelevant media. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  William L Jorgensen,et al.  Perspective on Free-Energy Perturbation Calculations for Chemical Equilibria. , 2008, Journal of chemical theory and computation.

[25]  M. Deininger,et al.  New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check , 2008, Expert opinion on investigational drugs.

[26]  S. Schenone,et al.  New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34+ cells , 2010, Investigational New Drugs.

[27]  Fabrizio Manetti,et al.  3D QSAR Models Built on Structure‐Based Alignments of Abl Tyrosine Kinase Inhibitors , 2009, ChemMedChem.

[28]  M. Radi,et al.  4-Amino-Substituted Pyrazolo[3,4-d]Pyrimidines: Synthesis and Biological Properties , 2009 .

[29]  T. Clackson,et al.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.

[30]  M. Radi,et al.  C6‐Unsubstituted Pyrazolo[3,4‐d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines , 2009, ChemMedChem.

[31]  E. Dreassi,et al.  2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors. , 2010, European journal of medicinal chemistry.

[32]  C. Brullo,et al.  New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms. , 2010, Current medicinal chemistry.

[33]  William L. Jorgensen,et al.  Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives. , 2010, Bioorganic & medicinal chemistry letters.

[34]  Wei-Sheng Huang,et al.  Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. , 2010, Journal of medicinal chemistry.

[35]  M. Radi,et al.  Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms. , 2010, Bioorganic & medicinal chemistry.

[36]  M. Radi,et al.  Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study. , 2011, Journal of medicinal chemistry.

[37]  M. Radi,et al.  New insights into small‐molecule inhibitors of Bcr‐Abl , 2011, Medicinal research reviews.

[38]  L. Stewart,et al.  Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. , 2011, Cancer cell.

[39]  M. Radi,et al.  Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells. , 2011, Bioorganic & medicinal chemistry letters.

[40]  T. Clackson,et al.  Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance , 2011, Chemical biology & drug design.

[41]  T. Clackson,et al.  Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models , 2012, Molecular Cancer Therapeutics.

[42]  H. Kantarjian,et al.  Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management , 2012, American journal of hematology.

[43]  Patric Schyman,et al.  Treatment of Halogen Bonding in the OPLS-AA Force Field; Application to Potent Anti-HIV Agents. , 2012, Journal of chemical theory and computation.